• Exemestane – AROMAPEX 25 – Overview

Exemestane is a steroidal aromatase inhibitor (AI) commonly known as Aromasin. It is the only pharmaceutical-grade brand of exemestane, protected under patent by Upjohn. It was approved by the FDA in 1999 and released in the U.S. in 2000.

Its primary medical use is the treatment of breast cancer in post-menopausal women. It later gained popularity among anabolic steroid users for controlling estrogen-related side effects and became common in some Post Cycle Therapy (PCT) protocols. SIXPEX PCT

---

• Classification & Mechanism

• Steroidal “suicide” aromatase inhibitor

• Irreversibly binds to the aromatase enzyme

• Blocks conversion of testosterone to estrogen

• Reduces serum estrogen levels (up to ~85%)

• Stimulates LH and FSH release

• Promotes natural testosterone production

• Slight androgenic activity

• May increase IGF-1 levels (unique among AIs)

---

• Medical Use

• Breast Cancer Treatment

• Reduces estrogen-dependent tumor growth

• Often used after SERM failure (e.g., tamoxifen)

• Effective in post-menopausal women

• Arimidex remains more commonly prescribed overall

---

• Use in Anabolic Steroid Cycles

• Estrogen Control On-Cycle

• Prevents gynecomastia

• Reduces water retention

• May help manage blood pressure

• Effective against aromatizing steroids

Common Aromatizing Steroids:

• Testosterone

• Dianabol

• Boldenone (moderate rate)

• Nandrolone (low aromatization + progestin activity)

Progestin-Based Compounds:

• Nandrolone

• Trenbolone (no aromatization but progestin-related risk)

Important Notes:

• No effect on DHT-derived steroids (cannot aromatize)

• Ineffective against Anadrol’s estrogenic activity (does not aromatize)

• SERMs required for receptor-level protection in such cases

---

• Use in Post Cycle Therapy (PCT)

• Potential Benefits

• Stimulates LH and FSH

• Boosts natural testosterone production

• Slight androgenic support

• May enhance IGF-1 levels

• Creates stronger anabolic environment

• Concerns

• Estrogen is necessary for health

• Important for immune function

• Essential for healthy cholesterol balance

• PCT goal is hormonal normalization

• Excessive estrogen suppression may hinder full recovery

Conclusion for PCT:

• SERMs preferred as first-line therapy

• AIs used only when clearly necessary

---

• Side Effects

• Common

• Fatigue or weakness

• Headaches

• Hot flashes

• Joint pain

• Elevated blood pressure

• Rare

• Depression

• Nausea or vomiting

• Bone Health

• Possible reduction in bone mineral density

• Increased osteoporosis risk

• Usually offset in steroid users due to anabolic effects

---

• Cholesterol Impact

• Can negatively affect HDL levels

• Alone: mild impact

• With testosterone: HDL reduction up to ~25%

• More pronounced at performance doses

• Risk amplified when combined with aromatizing steroids

Key Concern:

• Cardiovascular health often overlooked

• Diet and lipid monitoring essential

---

• AI vs. SERM Considerations

• Aromasin (AI)

• Lowers serum estrogen

• Prevents aromatization

• Stronger estrogen suppression

• SERMs (e.g., Nolvadex)

• Block estrogen at receptor level

• Do not lower serum estrogen

• Often sufficient for gynecomastia prevention

• Less impact on cholesterol

---

• Practical Guidance

• Use only when necessary

• Moderate cycles may require minimal AI

• Diet control helps reduce water retention

• Excess calories and carbohydrates worsen estrogenic effects

• Monitor cholesterol and blood pressure